EUVIMEDEUVIMED entdecken
Crossref

Adjuvant Homoeopathic Treatment for Respiratory Sequelae following COVID-19: A Pilot Study

Bindu Sharma, Jyoti Chhikara, Pankhuri Misra, Garima Srivastava, Divya Taneja, Saurabh Mittal, Pawan Sharma, Anil Khurana, Subhash Kaushik, Karan Madan, Vijay Hadda, Randeep Guleria und 1 weitere

Homœopathic Links · 01.09.2026 · 39 (03) · 147-156

DOI: 10.1055/s-0046-1827486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Homœopathic Links, erschienen am 01.09.2026. Verfasst von Bindu Sharma und 12 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent respiratory symptoms are frequently reported following recovery from COVID-19 infection and may affect pulmonary function, exercise capacity, and quality of life. While supportive therapies are commonly used in clinical practice, evidence regarding integrative approaches such as homoeopathy as an adjunct to conventional management remains limited. To evaluate clinical outcomes of individualized homoeopathic treatment administered as an adjunct to conventional care in patients experiencing respiratory sequelae following COVID-19 infection. A prospective, single-arm, open-label pilot clinical study was conducted from August 2021 to September 2022 at All India Institute of Medical Sciences, New Delhi, India. Participants aged ≥18 years with persistent respiratory symptoms following COVID-19 infection were recruited. Individualized homoeopathic medicines were prescribed as an adjunct to standard conventional management. Clinical outcomes included pulmonary function tests (PFTs), 6-minute walk test (6MWT), Numeric Rating Scale (NRS) for respiratory symptoms, Modified Medical Research Council Dyspnoea Scale (mMRC), and health-related quality of life assessed using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L). Assessments were conducted at baseline and after 3 months of follow-up. Of 162 individuals screened, 62 participants were enrolled and 50, who completed the study analyses demonstrated improvement in forced vital capacity (mean difference: 0.21 ± 0.05), 6-minute walk distance (6MWD; mean difference: 33.64 ± 9.52 meters), and symptom scores assessed using NRS, mMRC, and the EQ-5D-5L domains. Improvements observed in pulmonary function, exercise capacity, and symptom scores should be interpreted cautiously due to the single-arm pilot design. Larger randomized controlled trials with comparator groups are required.

Zitieren

APA

Sharma, B., Chhikara, J., Misra, P., Srivastava, G., Taneja, D., Mittal, S., Sharma, P., Khurana, A., Kaushik, S., Madan, K., Hadda, V., Guleria, R., & Mohan, A. (2026). Adjuvant Homoeopathic Treatment for Respiratory Sequelae following COVID-19: A Pilot Study. Homœopathic Links, 39(03), 147-156. https://doi.org/10.1055/s-0046-1827486

Vancouver

Sharma B, Chhikara J, Misra P, Srivastava G, Taneja D, Mittal S, et al. Adjuvant Homoeopathic Treatment for Respiratory Sequelae following COVID-19: A Pilot Study. Homœopathic Links. 2026;39(03):147-156. doi:10.1055/s-0046-1827486

BibTeX
@article{Sharma2026,
  author = {Sharma, Bindu and Chhikara, Jyoti and Misra, Pankhuri and Srivastava, Garima and Taneja, Divya and Mittal, Saurabh and Sharma, Pawan and Khurana, Anil and Kaushik, Subhash and Madan, Karan and Hadda, Vijay and Guleria, Randeep and Mohan, Anant},
  title = {Adjuvant Homoeopathic Treatment for Respiratory Sequelae following COVID-19: A Pilot Study},
  journal = {Homœopathic Links},
  year = {2026},
  volume = {39},
  number = {03},
  pages = {147--156},
  doi = {10.1055/s-0046-1827486}
}
Kostenlos starten →